Apogee Therapeutics, Inc.
APGE
$39.94
$1.614.20%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 20.66% | 18.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.30% | 33.01% | |||
| Operating Income | -29.30% | -33.01% | |||
| Income Before Tax | -37.09% | -44.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -37.13% | -44.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -37.13% | -44.96% | |||
| EBIT | -29.30% | -33.01% | |||
| EBITDA | -29.28% | -33.01% | |||
| EPS Basic | -36.03% | -44.23% | |||
| Normalized Basic EPS | -36.00% | -44.22% | |||
| EPS Diluted | -36.03% | -44.23% | |||
| Normalized Diluted EPS | -36.00% | -44.22% | |||
| Average Basic Shares Outstanding | 0.80% | 0.50% | |||
| Average Diluted Shares Outstanding | 0.80% | 0.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
